All In Biotech

Drug Trial Radar · NCT00402077

A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects

A Randomized, Parallel-Group, Multicenter Study to Examine the Safety, Tolerability, and Body Weight Effect of Subcutaneous Pramlintide Alone and in Combination With the Oral Antiobesity Agents Sibutramine or Phentermine in Overweight and Obese Subjects

Last checked: Nov 20, 2026Latest source record: Mar 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 258 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

258

Actual

Start

Nov 2006

Primary completion

Aug 2007

Study completion Aug 2007

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 22, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects.

Conditions

  • Overweight
  • Obesity

Interventions

  • pramlintide acetateDrug

    subcutaneous injection, three times a day, 120mcg

  • sibutramineDrug

    oral tablet, once a day, 10mg

  • phentermineDrug

    oral tablet, once a day, 37.5mg

  • placeboDrug

    subcutaneous injection, three times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All treatment-emergent adverse events occurring during the 24-week treatment periodTime frame: 24 weeks
  2. Absolute change in body weight from baseline to Week 12Time frame: 12 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Phoenix, Arizona

  • Research Site

    Chula Vista, California

  • Research Site

    La Jolla, California

  • Research Site

    Los Angeles, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Miami, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Louisville, Kentucky

  • Research Site

    New York, New York

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Statesville, North Carolina

  • Research Site

    Eugene, Oregon

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Austin, Texas

  • Research Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.